Halozyme's lead drug flops in PhIII, forcing CEO to ax 160 and reset focus on tech platform
Halozyme’s lead drug has crashed and burned in Phase III, forcing CEO Helen Torley to scrap the entire program, trigger a company restructuring to slash costs and shift focus to marketing its platform drug delivery technology.
The data from the Phase III of PEGPH20 in pancreatic cancer were bleak. Their drug $HALO combined with Abraxane actually fell short of a control arm dosed with gemcitabine and nab-paclitaxel alone — 11.2 months for their combo compared to 11.5 months for the control.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.